Erratum to: Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?
نویسندگان
چکیده
Author details Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Cardio-thoracic unit and Cystic Fibrosis Adult Center Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Milan, Italy. Department of Biomedical Science, Personalized Medicine Clinic: Asthma & Allergy Humanitas Clinical and Research Center, Humanitas University – Rozzano (Milano), Milan, Italy. Pneumology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain.
منابع مشابه
Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?
BACKGROUND As emphasized by international recommendations and largely confirmed by clinical experience, long-acting bronchodilators play a central role in the maintenance treatment of chronic obstructive pulmonary disease (COPD) due to their proven efficacy in reducing airflow obstruction and improving symptoms. MAIN BODY There are some important aspects to define with regard to inhalation th...
متن کاملNew combinations in the treatment of COPD: rationale for aclidinium–formoterol
The current guidelines on chronic obstructive pulmonary disease (COPD) recommend the prominent use of bronchodilators, including long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), while inhaled corticosteroids are recommended only in patients with severe disease or frequent exacerbations. LABA-LAMA combinations are indicated when single bronchodilators are insuffici...
متن کاملThe efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis
BACKGROUND Patients with chronic obstructive pulmonary disease (COPD) experience respiratory symptoms, which impair quality of life. This pooled analysis of two Phase III studies assessed the impact of aclidinium/formoterol on patients with COPD categorized by symptom status. METHODS Data were pooled from two 24-week, randomized, placebo-controlled studies of twice-daily aclidinium/formoterol...
متن کاملImprovement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study
BACKGROUND A previous Phase IIIb study (NCT01462929) in patients with moderate to severe COPD demonstrated that 6 weeks of treatment with aclidinium led to improvements in 24-hour bronchodilation comparable to those with tiotropium, and improvement of symptoms versus placebo. This post hoc analysis was performed to assess the effect of treatment in the symptomatic patient group participating in...
متن کاملThe impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis
Objective Long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are burdened by the potential risk of inducing cardiovascular serious adverse events (SAEs) in COPD patients. Since the risk of combining a LABA with a LAMA could be greater, we have carried out a quantitative synthesis to investigate the cardiovascular safety profile of LABA/LAMA fixed-dose combinations (F...
متن کامل